Analyst Serge Belanger of Needham maintained a Buy rating on Cytokinetics (CYTK – Research Report), retaining the price target of $72.00.
Serge Belanger’s rating is based on several strategic factors that highlight Cytokinetics’ potential for growth. The company is gearing up for the commercial launch of aficamten in the U.S. and EU, contingent on FDA approval expected by late September 2025. This preparation underscores confidence in the product’s market readiness and potential success.
Moreover, the upcoming results from the MAPLE-HCM trial, which are anticipated to be positive based on prior studies, could position aficamten as a leading treatment for hypertrophic cardiomyopathy. Additionally, Cytokinetics’ strong financial position, with significant cash reserves and a manageable cash utilization forecast, supports its operational plans. The anticipated FDA approval and strategic differentiation from competitors further justify the Buy rating, as the company enters a period rich with potential catalysts.